Skip to main
LFMD
LFMD logo

LifeMD (LFMD) Stock Forecast & Price Target

LifeMD (LFMD) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

LifeMD Inc. has demonstrated significant growth in its Telehealth segment, with an active subscriber base increasing by 14% year-over-year to reach 310,818 by the end of the third quarter of 2025, reflecting heightened consumer demand for virtual healthcare services. The company reported total revenue of $60.2 million, showcasing a 12.7% year-over-year growth, while Telehealth revenue specifically rose by 17.4%, indicating strong performance in this core area. Moreover, with the introduction of new offerings and strategic partnerships, LifeMD is positioned for sustained expansion within the evolving telehealth market, supported by the rising awareness and adoption of remote healthcare solutions.

Bears say

LifeMD Inc reported revenue of $60.2 million for the latest quarter, which represented a 13% year-over-year increase but fell short of consensus expectations of $62.6 million and other guidance estimates. The company's adjusted EBITDA of $5.1 million, up 20% year-over-year, also undershot projected figures, indicating operational challenges amid slowed revenue growth attributed to a reduction in aggressive marketing of compounded products. Additionally, the company has reduced its full-year 2025 revenue guidance for the telehealth segment to $192-193 million, citing competitive pressures from lower-cost alternatives in the market and potential risks related to patient acquisition, profitability, and competition, which collectively contribute to a negative outlook for the stock.

LifeMD (LFMD) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LifeMD and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LifeMD (LFMD) Forecast

Analysts have given LifeMD (LFMD) a Buy based on their latest research and market trends.

According to 7 analysts, LifeMD (LFMD) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LifeMD (LFMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.